Cosentyx (secukinumab) is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. The frequency of Cosentyx dosage adjustments depends on the patient's condition, response to treatment, and physician's recommendation.

According to the Cosentyx website [2], the recommended dosage for psoriatic arthritis and ankylosing spondylitis is 150 mg administered subcutaneously every four weeks after an initial loading dose of 150 mg at weeks 0, 1, 2, 3, and 4. For psoriasis, the recommended dosage is 300 mg at weeks 0, 1, 2, 3, and 4, followed by 300 mg every four weeks. However, the dosing schedule may be adjusted based on the patient's response to treatment and the physician's discretion.

A study published in the National Library of Medicine [3] evaluated the efficacy and safety of Cosentyx in psoriatic arthritis patients. The study found that patients who received Cosentyx had significant improvement in their condition, and the dosage was adjusted based on their response to treatment. The study concluded that Cosentyx is a safe and effective treatment for psoriatic arthritis, and the dosage should be adjusted based on the patient's response to treatment.

Drug Patent Watch [1] provides information on the patents and exclusivity of Cosentyx but does not provide information on dosage adjustments.

In summary, the frequency of Cosentyx dosage adjustments depends on the patient's condition, response to treatment, and physician's recommendation. The recommended dosage for psoriatic arthritis and ankylosing spondylitis is 150 mg administered subcutaneously every four weeks, while the recommended dosage for psoriasis is 300 mg at weeks 0, 1, 2, 3, and 4, followed by 300 mg every four weeks. The dosing schedule may be adjusted based on the patient's response to treatment and the physician's discretion. Cosentyx is a safe and effective treatment for psoriatic arthritis, and the dosage should be adjusted based on the patient's response to treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/psoriatic-arthritis/treatment-dosing
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422944/